Form 8-K - Current report:
SEC Accession No. 0001558370-21-013109
Filing Date
2021-10-12
Accepted
2021-10-12 06:03:27
Documents
15
Period of Report
2021-10-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20211011x8k.htm   iXBRL 8-K 39438
2 EX-99.1 plx-20211011xex99d1.htm EX-99.1 24466
3 GRAPHIC plx-20211011xex99d1002.jpg GRAPHIC 125150
4 GRAPHIC plx-20211011xex99d1001.jpg GRAPHIC 3809
  Complete submission text file 0001558370-21-013109.txt   371544

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20211011.xsd EX-101.SCH 3265
6 EX-101.LAB plx-20211011_lab.xml EX-101.LAB 16026
7 EX-101.PRE plx-20211011_pre.xml EX-101.PRE 10771
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20211011x8k_htm.xml XML 4912
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 211316592
SIC: 2836 Biological Products, (No Diagnostic Substances)